Law360, New York (July 23, 2010, 5:14 PM ET) -- Medicis Pharmaceutical Corp. has worked out a deal that resolves litigation stemming from Mylan Inc.’s launch of a generic version of acne treatment Solodyn and its plans to sell Medicis’ drug in new dosage levels.
Scottsdale, Ariz.-based Medicis on Thursday entered into a settlement and license agreement with Mylan and its affiliates Matrix Laboratories Ltd. and Mylan Pharmaceuticals Inc. that brings an end to Medicis’ two patent infringement cases over Solodyn extended-release tablets.
Mylan confirmed that Medicis’ patent for the drug is valid and enforceable, and...
Medicis, Mylan Settle Suits Over Acne Drug
To view the full article, take a free trial now.
